Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

H. pylori ulcer treatment NDAs understood to be set for Dec. 13 FDA advisory committee review.

Executive Summary

H. PYLORI DRUG THERAPY NDAs: FDA ADVISORY COMMITTEE REVIEW appears set for mid-December. FDA has applications pending for treatment regimens for Helicobacter pylori-induced gastric ulcers from at least three sponsors. The agency previewed some of the issues pertaining to H. pylori reviews at a joint meeting of the Gastrointestinal and Anti-Infective Drugs Advisory Committees on Oct. 26 ("The Pink Sheet" Nov. 6, p. 10). Reflecting the interest in the new ulcer regimens, FDA is apparently moving quickly back to the advisory committee for review of specific applications. FDA's Anti-Infective Drugs Advisory Committee has a meeting date scheduled for Dec. 13.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS027186

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel